Compare Dolby Laboratories, Inc. (DLB) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dolby Laboratories, Inc. vs Novo Nordisk A/S — how do they compare? Dolby Laboratories, Inc. trades at $59 (market cap $5.47B), while Novo Nordisk A/S trades at $38.6 (market cap $165.31B). The key difference: Novo Nordisk A/S is far larger — about 30.2× Dolby Laboratories, Inc.'s market cap, and Novo Nordisk A/S pays the higher dividend (4.71%). Which is the better fit depends on your goals — on Pluang, investors hold Dolby Laboratories, Inc. for 98 Days and Novo Nordisk A/S for 116 Days on average.
| DLB | NVO | |
|---|---|---|
Market Cap | $5.47B | $165.31B |
Volume | 1,058,284 | 11,432,838 |
Sector | Technology | Health |
52-Week High | $70.09 | $63.98 |
52-Week Low | $48.51 | $35.29 |
Typical Hold Time | 98 Days | 116 Days |
Enterprise Value | $4.85B | $179.56B |
Dividend Yield | 2.46% | 4.71% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DLB trades at $58.90, up 0.94% with bearish technical signals but strong fundamentals including 87.61% gross margins and consistent earnings beats. Recent expansion with Meta and leadership transition to Marc Whitten highlight growth initiatives. Cash flow improved significantly to $215.61M in 2025 from negative trends.
Analyst consensus targets $90.33 (53% upside) with 47% buy ratings, though technical indicators signal caution. Key risks include licensing volatility and execution during leadership change. Revenue stability and premium valuation at 24.87 P/E support long-term case if growth accelerates.
Novo Nordisk (NVO) trades at $38.26, up 1.95% today, with a bullish technical signal supported by oscillators like RSI at 20.06 (buy signal). The company shows strong fundamentals with a P/E of 9.66, net income margin of 35.35%, and consistent earnings beats in recent quarters. Recent news highlights pipeline developments, including a Wegovy pill study showing continued weight loss and a $4 billion licensing deal, though an FDA delay for a hemophilia drug poses a near-term headwind.
The outlook remains positive with a consensus price target of $44.67, implying 17% upside, driven by robust profitability and growth in GLP-1 therapies. Risks include competitive pressure from Eli Lilly, regulatory delays, and reliance on obesity/diabetes drugs. Analyst sentiment is bullish (59% buy ratings), but investors should monitor execution amid high expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dolby Laboratories, Inc.
Dolby Laboratories Inc develops audio and surround sound for cinema, broadcast, home audio systems, in-car entertainment systems, DVD players, games, televisions, and personal computers. The company generates three fourths of its revenue from licensing its technology to consumer electronics manufacturers around the world. The rest of revenue comes from equipment sales to professional producers and audio engineering services.
Read more on DLB →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
